Comparative evaluation of stability, efficacy, and sterility in five repackaged intravitreal anti-vascular endothelial growth factor medications

1. Hang, A., Feldman, S., Amin, A. P., Ochoa, J. A. R. & Park, S. S. Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. Pharmaceuticals 16, 1140. https://doi.org/10.3390/ph16081140 (2023).

   Google Scholar 

2. Dorrell, M., Uusitalo-Jarvinen, H., Aguilar, E. & Friedlander, M. Ocular neovascularization: basic mechanisms and therapeutic advances. Surv. Ophthalmol. 52, S3-S19. (2007) https://doi.org/10.1016/j.survophthal.2006.10.017

3. Heloterä, H. & Kaarniranta, K. A linkage between angiogenesis and inflammation in neovascular age-related macular degeneration. Cells 11, 3453. https://doi.org/10.3390/cells11213453 (2022).

   Google Scholar 

4. Tsai, A. S. et al. Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF). Prog. Retin. Eye Res. 88, 101018. https://doi.org/10.1016/j.preteyeres.2021.101018 (2022).

   Google Scholar 

5. Uludag, G. et al. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: What we have learned and what should we learn further? Expert Opin. Biol. Ther. 22, 1275–1291. https://doi.org/10.1080/14712598.2022.2100694 (2022).

   Google Scholar 

6. Imazeki, M. et al. Anti-VEGF therapy reduces inflammation in diabetic macular edema. Ophthalmic Res. 64, 43–49. https://doi.org/10.1159/000508953 (2021).

   Google Scholar 

7. Ferro Desideri, L., Traverso, C. E., Nicolò, M. & Munk, M. R. Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration. Pharmaceutics 15, 1413. https://doi.org/10.3390/pharmaceutics15051413 (2023).

   Google Scholar 

8. WellsJA, G. AyalaARDiabetic retinopathy clinical research network. Aflibercept, bevacizumab, or Ranibizumab for diabetic macular edema. N Engl. J. Med. 372, 1193–1203 (2015).

   Google Scholar 

9. Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G. & Hawkins, B. S. Anti-vascular endothelial growth factor for neovascular age‐related macular degeneration. Cochrane Database Syst. Reviews. https://doi.org/10.1002/14651858.CD005139.pub3 (2014).

   Google Scholar 

10. Heier, J. S. et al. Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial. Ophthalmology 119, 802–809. https://doi.org/10.1016/j.ophtha.2011.12.005 (2012).

    Google Scholar 

11. Baker-Schena, L. & Expensive (eds) drugs. EyeNet Magazine, 39–44 (2017).

12. Brown, G. C., Brown, M. M., Rapuano, S. B. & Boyer, D. A cost-benefit analysis of VEGF-inhibitor therapy for neovascular age-related macular degeneration in the united States. Am. J. Ophthalmol. 223, 405–429. https://doi.org/10.1016/j.ajo.2020.07.010 (2021).

    Google Scholar 

13. Sam-Oyerinde, O. A. & Patel, P. J. Real-world outcomes of anti-VEGF therapy in diabetic macular oedema: Barriers to treatment success and implications for low/lower-middle-income countries. Ophthalmol. Therapy. 12, 809–826. https://doi.org/10.1007/s40123-023-00672-6 (2023).

    Google Scholar 

14. Juhong, J. et al. The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration. Sci. Rep. 12, 2971. https://doi.org/10.1038/s41598-022-06831-2 (2022).

    Google Scholar 

15. Cao, S., Cui, J., Matsubara, J. & Forooghian, F. Long-term in vitro functional stability of compounded Ranibizumab and Aflibercept. Can. J. Ophthalmol. 52, 273–276. https://doi.org/10.1016/j.jcjo.2016.11.012 (2017).

    Google Scholar 

16. Parikh, R. et al. A multinational comparison of anti–vascular endothelial growth factor use: The United States, the United Kingdom, and Asia-Pacific. Ophthalmol. Retina. 3, 16–26. https://doi.org/10.1016/j.oret.2018.08.002 (2019).

    Google Scholar 

17. Blom, K., Bragadóttir, R., Sivertsen, M. S., Moe, M. C. & Jørstad, Ø. K. Does pharmaceutical compounding of vascular endothelial growth factor inhibitors for intravitreal use alter the risk of post-injection endophthalmitis? Ocul. Immunol. Inflamm. 30, 713–716. https://doi.org/10.1080/09273948.2020.1820530 (2022).

    Google Scholar 

18. Tatsumi, T. Current treatments for diabetic macular edema. Int. J. Mol. Sci. 24, 9591. https://doi.org/10.3390/ijms24119591 (2023).

    Google Scholar 

19. Chen, Y. H. et al. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months. J. Ocul. Pharmacol. Ther. 25, 65–70. https://doi.org/10.1089/jop.2008.0043 (2009).

    Google Scholar 

20. Khalili, H., Sharma, G., Froome, A., Khaw, P. T. & Brocchini, S. Storage stability of bevacizumab in polycarbonate and polypropylene syringes. Eye 29, 820–827. https://doi.org/10.1038/eye.2015.28 (2015).

    Google Scholar 

21. Gjølberg, T. T. et al. A silicone oil-free syringe tailored for intravitreal injection of biologics. Front. Ophthalmol. 2, 882013. https://doi.org/10.3389/fopht.2022.882013 (2022).

    Google Scholar 

22. Sivertsen, M. S. et al. Pharmaceutical compounding of Aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties. Sci. Rep. 8, 2101. https://doi.org/10.1038/s41598-018-20525-8 (2018).

    Google Scholar 

23. de Farah, L. Evaluation of Aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding. Int. J. Retina Vitreous. 4, 1–7. https://doi.org/10.1186/s40942-018-0143-x (2018).

    Google Scholar 

24. Jørstad, Ø. K. et al. Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties. Int. J. Retina Vitreous. 9, 65. https://doi.org/10.1186/s40942-023-00507-3 (2023).

    Google Scholar 

25. Taschauer, A. et al. Faricimab maintains substance integrity and sterility after compounding and storage in two different polypropylene syringe types. Eye https://doi.org/10.1038/s41433-024-03511-5 (2024).

26. Gaudy, A. Jr, Abu-Niaaj, F. & Gaudy, E. Statistical study of the spot-plate technique for viable-cell counts. Appl. Microbiol. 11, 305–309. https://doi.org/10.1128/am.11.4.305-309.1963 (1963).

    Google Scholar 

27. Convention, U. S. P. USP General Chapter < 71>, Sterility tests, (2016). https://www.usp.org/sites/default/files/usp/document/harmonization/gen-method/q11_pf_ira_34_6_2008.pdf

28. Convention, U. S. P. USP General Chapter < 62>, Microbiological examination of nonsterile products: tests for specified microorganisms (2016). https://www.usp.org/sites/default/files/usp/document/harmonization/gen-method/q05b_pf_ira_34_6_2008.pdf

29. Yannuzzi, N. A. et al. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol. 133, 32–39. https://doi.org/10.1001/jamaophthalmol.2014.3591 (2015).

    Google Scholar 

30. Örnek, K., Karahan, Z. C., Ergin, A., Tekeli, A. & Tekeli, O. Bevacizumab sterility in multiple doses from a single-use vial. Ann. Pharmacother. 42, 1425–1428. https://doi.org/10.1345/aph.1L270 (2008).

    Google Scholar 

31. Moreno, M. et al. Study of stability and biophysical characterization of Ranibizumab and Aflibercept. Eur. J. Pharm. Biopharm. 108, 156–167. https://doi.org/10.1016/j.ejpb.2016.09.003 (2016).

    Google Scholar 

32. Palmer, J., Amoaku, W. & Kamali, F. Quality of bevacizumab compounded for intravitreal administration. Eye 27, 1090–1097. https://doi.org/10.1038/eye.2013.139 (2013).

    Google Scholar 

33. Das, T. et al. Safety, sterility and stability of direct-from‐vial multiple dosing intravitreal injection of bevacizumab. Clin. Exp. Ophthalmol. 43, 466–473. https://doi.org/10.1111/ceo.12489 (2015).

    Google Scholar 

34. Murray, P. R., Baron, E. J., Jorgensen, J. H. & Landry, M. L. Manual of clinical microbiology (Amer society for microbiology) (2007).

35. Chang, D. P. et al. Long-term stability of anti-vascular endothelial growth factor (a-VEGF) biologics under physiologically relevant conditions and its impact on the development of long-acting delivery systems. J. Pharm. Sci. 110, 860–870 (2021).

    Google Scholar 

36. Convention, U. S. P. USP General Chapter < 795>, Pharmaceutical compounding – nonsterile preparations, (2024). https://www.usp.org/compounding/general-chapter-795

37. Convention, U. S. P. USP General Chapter < 797>, Pharmaceutical compounding – sterile preparations, (2024). https://www.usp.org/compounding/general-chapter-797

38. Gasteiger, E. et al. Protein identification and analysis tools on the expasy server. Proteom. Protocols Handb. https://doi.org/10.1385/1-59259-890 (2005).

Download references

Declarations.

This research is supported in part by IPS grants from the Faculty of Science, Mahidol University (to Danaya Pakotiprapha and Sittinan Chanarat), and by the mid-career researcher grant from National Research Council of Thailand (NRCT) and Mahidol University (N42A670557) (to Varodom Charoensawan). The sponsors or funding organization had no role in the design or conduct of this research.

Author notes

1. Panintorn Thunwiriya, Tanaporn Phetruen, Phaewa Chaiwijit these three are co-first authors and they contributed equally to thiswork.

   Varodom Charoensawan, Sittinan Chanarat, Danaya Pakotiprapha and Prut Hanutsaha have contributed equally to this work.

Authors and Affiliations

1. School of Ophthalmology, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima, Thailand

   Panintorn Thunwiriya

2. Center for Excellence in Protein and Enzyme Technology, Faculty of Science, Mahidol University, Bangkok, Thailand

   Tanaporn Phetruen, Sittinan Chanarat & Danaya Pakotiprapha

3. Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand

   Tanaporn Phetruen, Varodom Charoensawan, Sittinan Chanarat & Danaya Pakotiprapha

4. Division of Medical Bioinformatics, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

   Phaewa Chaiwijit & Varodom Charoensawan

5. Department of Biochemistry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

   Phaewa Chaiwijit & Varodom Charoensawan

6. Siriraj Genomics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

   Phaewa Chaiwijit & Varodom Charoensawan

7. Department of Ophthalmology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

   Chaiyawat Tonawannakorn & Prut Hanutsaha

8. Department of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand

   Kanokwan Dekham

9. Department of Medical Sciences, National Institute of Health, Ministry of Public Health, Nonthaburi, Thailand

   Nalumon Thadtapong

10. Center for Advanced Therapeutics, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand

    Soraya Chaturongakul

11. School of Chemistry, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima, Thailand

    Varodom Charoensawan

Contributions

Conceptualization: PT, VC, SChanarat, DP, PHMethodology: PT, SChaturongakul, VC, SChanarat, DP, PHValidation: TP, PC, KD, NTFormal analysis: TP, PC, KD, NTInvestigation: PT, SChaturongakul, VC, SChanarat, DP, PHResources: CT, SChaturongakul, SChanarat, DP, PHWriting – Original Draft: PT, TP, PC, VC, SChanarat, DPWriting – Review & Editing: All authorsVisualization: TP, PC, KD, NTSupervision: PT, SChaturongakul, VC, SChanarat, DP, PH.

Corresponding authors

Correspondence to Panintorn Thunwiriya, Varodom Charoensawan, Sittinan Chanarat, Danaya Pakotiprapha or Prut Hanutsaha.

Competing interests

The authors declare no competing interests.

Declaration of generative AI and AI-assisted technologies in the writing process

During the preparation of this work, the authors used ChatGPT and Google Gemini, exclusively to improve readability and for grammar check. After using these tools, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions